PR Newswire·Nov 6, 2026, 4:05 PM ET

InMed Pharmaceuticals Completes Closing of Merger with Mentari Therapeutics

InMed Pharmaceuticals Inc. completed its merger with pre-merger Mentari Therapeutics Inc. & changed its name to Mentari Therapeutics, Inc.
The combined company will trade on the Nasdaq Capital Market under the ticker symbol "MTRI" starting November 9, 2026.
The company redomesticated from British Columbia, Canada to the State of Nevada immediately prior to the merger closing.
Pre-merger Mentari secured approximately $490 million in gross proceeds from private financings, including the conversion of $50.0 million in convertible notes plus accrued interest.
Outstanding shares of pre-merger Mentari common stock were converted into the right to receive approximately 0.20065 shares of the combined company's common stock, adjusted for a 1-for-10 reverse stock split.
Holders of the former company's shares as of November 5, 2026, received one non-transferable contingent value right per share held.
Mentari Therapeutics is a clinical-stage biotechnology company based in Waltham, MA, developing next-generation migraine therapies including MT-001 & MT-002.